Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
1.
Antimicrob Agents Chemother ; 67(6): e0024923, 2023 06 15.
Artículo en Inglés | MEDLINE | ID: mdl-37219437

RESUMEN

Present evidence suggests that the administration of antibiotics, particularly aminopenicillins, may increase the risk of rash in children with infectious mononucleosis (IM). This retrospective, multicenter cohort study of children with IM was conducted to explore the association between antibiotic exposure in IM children and the risk of rash. A robust error generalized linear regression was performed to address the potential cluster effect, as well as confounding factors such as age and sex. A total of 767 children (aged from 0 to 18 years) with IM from 14 hospitals in Guizhou Province were included in the final analysis. The regression analysis implied that exposure to antibiotics was associated with a significantly increased incidence of overall rash in IM children (adjusted odds ratio [AOR], 1.47; 95% confidence interval [CI], ~1.04 to 2.08; P = 0.029). Of 92 overall rash cases, 43 were probably related to antibiotic exposure: two cases (4.08%) in the amoxicillin-treated group and 41 (8.15%) in the group treated with other antibiotics. Regression analysis indicated that the risk of rash induced by amoxicillin in IM children was similar to that induced by other penicillins (AOR, 1.12; 95% CI, ~0.13 to 9.67), cephalosporins (AOR, 2.45; 95% CI, ~0.43 to 14.02), or macrolides (AOR, 0.91; 95% CI, ~0.15 to 5.43). Antibiotic exposure may be associated with an increased risk of overall rash in IM children, but amoxicillin was not found to be associated with any increased risk of rash during IM compared to other antibiotics. We suggest that clinicians be vigilant against the occurrence of rash in IM children receiving antibiotic therapy, rather than indiscriminately avoiding prescribing amoxicillin.


Asunto(s)
Exantema , Mononucleosis Infecciosa , Humanos , Niño , Antibacterianos/efectos adversos , Estudios Retrospectivos , Mononucleosis Infecciosa/tratamiento farmacológico , Mononucleosis Infecciosa/inducido químicamente , Estudios de Cohortes , Amoxicilina/efectos adversos , Exantema/inducido químicamente , Exantema/tratamiento farmacológico , Exantema/epidemiología , Penicilinas/efectos adversos
4.
Rheumatol Int ; 29(7): 825-6, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19034455

RESUMEN

The objective is to report a case of atypical acute infectious mononucleosis in a juvenile ankylosing spondylitis patient who was treated with infliximab. A 20-year-old man was hospitalized for the evaluation of lymphadenopathy and systemic symptoms. His symptoms developed at the eighth week of the infliximab treatment and he required hospitalization. Lymph node biopsy was performed and he was diagnosed as atypical infectious mononucleosis (absence of fever, pharyngitis, lymphocytosis and negative atypical lymphocytosis on blood smear). Infections have become major concerns in patients treated with TNF-blocking agents. In theoretical base, it is not surprising as TNF-alpha has a crucial role in the body's defense against both bacterial and viral invasion. Blocking the action of TNF may also change the course of the disease and could lead to a delay in the diagnosis. TNF-alpha-blocking treatment may mask the typical symptoms of infectious mononucleosis and atypical cases should be included in the differential diagnosis of lymphadenopathy in patients receiving anti-TNF-alpha agents.


Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Inmunosupresores/efectos adversos , Mononucleosis Infecciosa/inducido químicamente , Mononucleosis Infecciosa/inmunología , Espondilitis Anquilosante/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Antirreumáticos/efectos adversos , Errores Diagnósticos , Diagnóstico Precoz , Humanos , Tolerancia Inmunológica/efectos de los fármacos , Tolerancia Inmunológica/inmunología , Mononucleosis Infecciosa/virología , Infliximab , Enfermedades Linfáticas/inducido químicamente , Enfermedades Linfáticas/inmunología , Enfermedades Linfáticas/virología , Masculino , Infecciones Oportunistas/inducido químicamente , Infecciones Oportunistas/inmunología , Infecciones Oportunistas/virología , Medición de Riesgo , Espondilitis Anquilosante/inmunología , Factor de Necrosis Tumoral alfa/deficiencia , Adulto Joven
5.
Gastroenterol. hepatol. (Ed. impr.) ; 31(5): 289-292, mayo 2008.
Artículo en Español | IBECS | ID: ibc-84645

RESUMEN

El uso de fármacos inmunomoduladores para el tratamientode la enfermedad inflamatoria intestinal es cada vez más común.Las complicaciones infecciosas son uno de los efectosadversos más habituales asociados a este tipo de fármacos.En los últimos años se ha prestado especial atención a determinadasinfecciones latentes dado que, en pacientes bajotratamiento inmunomodulador, pueden reactivarse y cursarde forma fatal. Por esta razón, ya se han establecido estrategiasde cribado para el virus de la hepatitis B o la tuberculosisantes de iniciar este tipo de terapias. El virus de Epstein-Barr es un herpesvirus cuya primoinfección suele cursar deforma asintomática, pero puede presentarse con formas clínicasagresivas o quedar acantonado y ser causa del posteriordesarrollo de linfoma. Se presentan 2 casos de mononucleosisinfecciosa de presentación atípica en pacientes conenfermedad inflamatoria intestinal tratados con azatioprinay se revisa la literatura médica en relación con la actitudque cabe adoptar en este tipo de pacientes (AU)


The use of immunomodulators for the treatment of inflammatorybowel disease is increasing. One of the most commonadverse effects associated with this kind of drugs are infectiouscomplications. In recent years, special attention hasbeen paid to certain latent infections which, in patients underimmunomodulatory therapy, can be reactivated andprove lethal. Consequently, preventive actions have beenadopted, such as screening for hepatitis B virus and tuberculosisinfection before starting these treatments.Primary infection with the Epstein-Barr herpesvirus isusually asymptomatic. However, this virus can have an aggressivecourse and even lead to the development of lymphoma.We report two cases of atypical infectious mononucleosisin patients with inflammatory bowel disease under azathioprinetherapy and review the available evidence on the mostappropriate therapeutic approach in this subset of patients (AU)


Asunto(s)
Humanos , Azatioprina/efectos adversos , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Mononucleosis Infecciosa/inducido químicamente , Enfermedades Inflamatorias del Intestino/complicaciones , Herpesvirus Humano 4/patogenicidad , Factores Inmunológicos/efectos adversos
10.
Acta gastroenterol. latinoam ; 30(2): 73-6, 2000. ilus, tab
Artículo en Español | LILACS | ID: lil-269938

RESUMEN

Presentamos un caso poco frecuente de insuficiencia hepática aguda por difenilhidantoína en una joven de 18 años. La paciente fue tratada con dicho fármaco inmediatamente después de un parto normal por presentar convulsiones clónicas secundarias a un quiste aracnoideo del lóbulo temporal izquierdo. La paciente presentó un "tipo mononucleosis like" tal como ha sido descripto previamente. La enferma mejoró su función hepática estando en lista de espera para transplante ortotópico hepático y se recuperó totalmente hasta alcanzar el alta definitiva de dos meses después sin haber presentado manifestaciones de encefalopatía hepática en ningún momento de la evolución. La ausencia de encefalopatía hepática, tal como ocurrió en nuestra paciente, no fue señalada en ninguno de los pocos casos de insuficiencia hepática por difenilhidantoína comunicados previamente. Nos estimulan a poner en conocimiento de la comunidad médica un nuevo caso de insuficiencia hepática aguda por difenilhidantoína: 1) La ausencia de encefalopatía hepática (comunicada por primera vez en un caso de insuficiencia hepática aguda por difenilhidantoína. 2) La baja frecuencia de insuficiencia hepática aguda por difenilhidantoína. 3) La forma típica de presentación como "Síndrome Mononucleosis like" con la posibilidad que ella convella de confundir esta entidad con una infección por virus de Ebstein Bar.


Asunto(s)
Humanos , Femenino , Adolescente , Anticonvulsivantes/efectos adversos , Fallo Hepático Agudo/inducido químicamente , Fenitoína/efectos adversos , Biomarcadores/sangre , Encefalopatía Hepática , Mononucleosis Infecciosa/inducido químicamente , Mononucleosis Infecciosa/diagnóstico , Mononucleosis Infecciosa/patología , Fallo Hepático Agudo/diagnóstico , Fallo Hepático Agudo/patología , Periodo Posparto
11.
Acta gastroenterol. latinoam ; 30(2): 73-6, 2000. ilus, tab
Artículo en Español | BINACIS | ID: bin-11880

RESUMEN

Presentamos un caso poco frecuente de insuficiencia hepática aguda por difenilhidantoína en una joven de 18 años. La paciente fue tratada con dicho fármaco inmediatamente después de un parto normal por presentar convulsiones clónicas secundarias a un quiste aracnoideo del lóbulo temporal izquierdo. La paciente presentó un "tipo mononucleosis like" tal como ha sido descripto previamente. La enferma mejoró su función hepática estando en lista de espera para transplante ortotópico hepático y se recuperó totalmente hasta alcanzar el alta definitiva de dos meses después sin haber presentado manifestaciones de encefalopatía hepática en ningún momento de la evolución. La ausencia de encefalopatía hepática, tal como ocurrió en nuestra paciente, no fue señalada en ninguno de los pocos casos de insuficiencia hepática por difenilhidantoína comunicados previamente. Nos estimulan a poner en conocimiento de la comunidad médica un nuevo caso de insuficiencia hepática aguda por difenilhidantoína: 1) La ausencia de encefalopatía hepática (comunicada por primera vez en un caso de insuficiencia hepática aguda por difenilhidantoína. 2) La baja frecuencia de insuficiencia hepática aguda por difenilhidantoína. 3) La forma típica de presentación como "Síndrome Mononucleosis like" con la posibilidad que ella convella de confundir esta entidad con una infección por virus de Ebstein Bar. (Au)


Asunto(s)
Humanos , Femenino , Adolescente , Fallo Hepático Agudo/inducido químicamente , Fenitoína/efectos adversos , Anticonvulsivantes/efectos adversos , Fallo Hepático Agudo/diagnóstico , Fallo Hepático Agudo/patología , Periodo Posparto , Mononucleosis Infecciosa/inducido químicamente , Mononucleosis Infecciosa/diagnóstico , Mononucleosis Infecciosa/patología , Encefalopatía Hepática , Biomarcadores/sangre
12.
Cutis ; 64(2): 91-6, 1999 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10467499

RESUMEN

A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. His illness was also characterized by a palpable spleen tip, marked lower extremity and scrotal edema, and generalized lymphadenopathy. The patient had leukocytosis with a large percentage of atypical lymphocytes on peripheral smear and liver dysfunction. Titers for Epstein-Barr virus, hepatitis B, toxoplasmosis; and cytomegalovirus were all negative. Human immunodeficiency virus-1 viral load and antibodies were also negative. Marked improvement was noted after the discontinuation of minocycline and the use of systemic corticosteroids. With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis-like syndrome produced by the minocycline ingestion.


Asunto(s)
Antibacterianos/efectos adversos , Hipersensibilidad a las Drogas/diagnóstico , Mononucleosis Infecciosa/diagnóstico , Minociclina/efectos adversos , Acné Vulgar/tratamiento farmacológico , Adulto , Diagnóstico Diferencial , Hipersensibilidad a las Drogas/etiología , Humanos , Mononucleosis Infecciosa/inducido químicamente , Masculino , Síndrome
13.
Gut ; 36(2): 311-3, 1995 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-7883236

RESUMEN

A 19 year old man with a history of Crohn's disease treated with azathioprine and prednisone, died after a primary infection with Epstein-Barr virus. He had the characteristics of the virus associated haemophagocytic syndrome, a rare complication of viral infections, which consists of fever, constitutional symptoms, hepatosplenomegaly, liver function and coagulation abnormalities, and hypertriglyceridaemia. Additionally, there was pain, cytopenia, and histiocytic hyperplasia in the bone marrow, spleen, or lymph nodes. This severe complication has been reported previously in renal transplant patients, but not in those with inflammatory bowel disease taking azathioprine. The immunosuppressive therapy may have contributed to this fatal complication of infectious mononucleosis, and this complication should be considered when treating a patient with inflammatory bowel disease with azathioprine.


Asunto(s)
Azatioprina/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Mononucleosis Infecciosa/inducido químicamente , Adulto , Azatioprina/efectos adversos , Enfermedad de Crohn/complicaciones , Resultado Fatal , Humanos , Terapia de Inmunosupresión/efectos adversos , Masculino
14.
J Formos Med Assoc ; 90(2): 202-5, 1991 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-1678417

RESUMEN

Diphenylhydantoin-induced hepatitis and mononucleosis are uncommon in children. The occurrence of these two diseases in the same individual, with progression to hepatic failure is rare and has not been reported in infants. This report represents a 6-month-old male infant who developed an infectious mononucleosis-like syndrome and hepatic failure 16 days after diphenylhydantoin administration. He took this anticonvulsant for controlling seizures after a head injury. Fever, skin rash, hepatosplenomegaly, lymphadenopathy, and atypical lymphocytosis led to the initial diagnosis of infectious mononucleosis. However, negative heterophil antibody did not support the diagnosis. Jaundice ensued in the following course and became more and more profound. Meanwhile, physical examination showed shrinking in liver size. Negative virology studies, including Epstein-Barr virus, cytomegalovirus, and hepatitis B virus, excluded them as causative agents. The patient lapsed into a stage I hepatic coma, but gradually recovered clinically and biochemically after eight successive exchange transfusions and supportive care. Two liver biopsies were performed 20 and 50 days after the onset of disease, respectively. Remarkable hepatic parenchymal loss, cholestasis, and fatty change were found on histologic examination of the first biopsy specimen, and portal fibrosis was noted on the second.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Síndrome de Fatiga Crónica/inducido químicamente , Mononucleosis Infecciosa/inducido químicamente , Fenitoína/efectos adversos , Humanos , Lactante , Masculino
15.
Gastroenterol Jpn ; 24(1): 65-9, 1989 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-2707554

RESUMEN

A case of systemic lupus erythematosus (SLE) with mononucleosis-like hepatic injury was described. An emergent cesarean section was performed in a 25 yr-old house wife at 34 weeks gestation, followed by administration of several antibiotics. After the surgery she complained of high fever, hepatomegaly and dull right hypochondralgia, and mild liver dysfunction was also found. The liver biopsy showed prominent mononuclear cell infiltration in the sinusoids with minimum hepatocellular necrosis and mild triaditis, resembling hepatic lesion in infectious mononucleosis (mononucleosis-like injury). There were no clinical and serological features suggestive of infectious mononucleosis. This hepatic lesion was thought to be a manifestation of allergic reaction to drugs to which the lymphocyte stimulation test was found to be positive. Immunological abnormalities inherent in SLE might be related to occurrence of such allergic drug reaction.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas , Mononucleosis Infecciosa/inducido químicamente , Lupus Eritematoso Sistémico/complicaciones , Adulto , Cefoxitina/efectos adversos , Cefalosporinas/efectos adversos , Dibekacina/efectos adversos , Femenino , Humanos , Indometacina/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...